Sera Prognostics Q4 2021 revenue $26k, net loss $12.5M; losses widen as commercial ops scale

SERA PROGNOSTICS, INC.

Q4 2021 revenue rose to $26k from $6k YoY; net loss of $12.5M vs $5.4M.
Full-year 2021 revenue $82k, total operating expenses $35.5M (up from $18M).
Cash and securities totaled $139.9M as of Dec 31, 2021.
CMS set Medicare payment rate of $750 for PreTRM test; added to NASDAQ Biotechnology Index.
R&D spend increased to $3.1M in Q4; SG&A jumped to $9.5M on higher headcount and public company costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.